Bone-Seeking Targeted Radio-Nuclide Therapy BT-RNT) in Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Shifting from Palliation to Improving SurvivalVimoj J Nair1, Colin Malone2, Patricia Moretto3, Eugene Leung3 and Shawn Malone1*
- *Corresponding Author:
- Shawn Malone
Associate Professor, Department of Radiation Oncology
The Ottawa Hospital Cancer Centre, 501 Smyth Road
Ottawa, Ontario, K1H 8L6, Canada
E-mail: [email protected]
Received date: October 16, 2014; Accepted date: November 28, 2014; Published date: December 01, 2014
Citation: Nair VJ, Malone C, Moretto P, Leung E, Malone S (2014) Bone-Seeking Targeted Radio-Nuclide Therapy (BT-RNT) in Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Shifting from Palliation to Improving Survival. J Nucl Med Radiat Ther 5:202. doi:10.4172/2155-9619.1000202
Copyright: © 2014 Nair VJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: The purpose of this article is to review the role of bone-seeking targeted radionuclide therapy (BT-RNT) in metastatic prostate cancer. The mechanisms of actions, radiobiology and clinical benefits of BT-RNTs will be reviewed.
Methods: Relevant studies of CRPC and targeted therapies were identified from literature and clinical trial databases, websites, and conference abstracts.
Results: BT-RNT in mCRPC has a proven beneficial palliative role in treatment of patients with mCRPC. The use of these agents as a monotherapy as well as combination with other palliative therapies are evolving. Among the various BT-RNT’s the alpha emitter 223Ra which is highly targeted and well tolerated has shown significant clinical benefit and survival advantage in this patient population.
Conclusion: BT-RNT represents an exciting treatment option for patients with mCRPC. 223Ra represents a new treatment paradigm for patients with mCRPC.